.

S27 - LPL-SRINAGAR
140-A, KAK SARAI, KARAN NAGAR,
SRINAGAR- 190010, J&K
SRINAGAR

Name : Mr. ISHFAQ SHAFIQ Collected : 2/7/2021 10:03:00AM

Received : 2/7/2021 10:15:01AM
Lab No. : 311032063 Age: 29 Years Gender: Male Reported : 3/7/2021 4:28:12PM
A/c Status : P Ref By : Dr. ZEESHAN Report Status : Final

Test Name Results Units Bio. Ref. Interval

LIVER PANEL 1; LFT,SERUM

(Spectrophotometry)

AST (SGOT) 106 U/L <50

ALT (SGPT) 177 U/L <50

AST:ALT Ratio 0.60 <1.00

GGTP 38 U/L <55

Alkaline Phosphatase (ALP) 120 U/L 30 - 120

Bilirubin Total 1.44 mg/dL 0.30 - 1.20

Bilirubin Direct 0.34 mg/dL <0.30

Bilirubin Indirect 1.10 mg/dL <1.10

Total Protein 9.19 g/dL 6.40 - 8.30

Albumin 5.20 g/dL 3.50 - 5.20

A : G Ratio 1.30 0.90 - 2.00

Note
1. In an asymptomatic patient, Non alcoholic fatty liver disease (NAFLD) is the most common cause of
increased AST, ALT levels. NAFLD is considered as hepatic manifestation of metabolic syndrome.

PatientReportSCSuperPanel.GENERAL_PANEL_ANALYTE_SC (Version: 6)

*311032063*
Page 1 of 6
.

S27 - LPL-SRINAGAR
140-A, KAK SARAI, KARAN NAGAR,
SRINAGAR- 190010, J&K
SRINAGAR

Name : Mr. ISHFAQ SHAFIQ Collected : 2/7/2021 10:03:00AM

Received : 2/7/2021 10:15:01AM
Lab No. : 311032063 Age: 29 Years Gender: Male Reported : 3/7/2021 4:28:12PM
A/c Status : P Ref By : Dr. ZEESHAN Report Status : Final

Test Name Results Units Bio. Ref. Interval

2. In most type of liver disease, ALT activity is higher than that of AST; exception may be seen in Alcoholic
Hepatitis, Hepatic Cirrhosis, and Liver neoplasia. In a patient with Chronic liver disease, AST:ALT
ratio>1 is highly suggestive of advanced liver fibrosis.
3. In known cases of Chronic Liver disease due to Viral Hepatitis B & C, Alcoholic liver disease or NAFLD,
Enhanced liver fibrosis (ELF) test may be used to evaluate liver fibrosis.
4. In a patient with Chronic Liver disease, AFP and Des-gamma carboxyprothrombin (DCP)/PIVKA II can
be used to assess risk for development of Hepatocellular Carcinoma.

PatientReportSCSuperPanel.GENERAL_PANEL_ANALYTE_SC (Version: 6)

*311032063*
Page 2 of 6
.

S27 - LPL-SRINAGAR
140-A, KAK SARAI, KARAN NAGAR,
SRINAGAR- 190010, J&K
SRINAGAR

Name : Mr. ISHFAQ SHAFIQ Collected : 2/7/2021 10:03:00AM

Received : 2/7/2021 10:15:01AM
Lab No. : 311032063 Age: 29 Years Gender: Male Reported : 3/7/2021 4:28:12PM
A/c Status : P Ref By : Dr. ZEESHAN Report Status : Final

Test Name Results Units Bio. Ref. Interval

PROTHROMBIN TIME STUDIES

(Electromechanical Clot Detection)

Mean Normal Prothrombin Time (PT) 13.20

Patient value 11.70 sec 11.99 - 14.36

Prothrombin Ratio (PR) 0.89

International Normalized Ratio (INR) 0.90 0.90 - 1.10

Note
1. INR is the parameter of choice in monitoring adequacy of oral anticoagulant therapy. Appropriate
therapeutic range varies with the disease and treatment intensity
2. Prolonged INR suggests potential bleeding disorder / bleeding complications
3. Results should be clinically correlated
4. Test conducted on Citrated plasma

Recommended Therapeutic range for Oral Anticoagulant therapy

INR 2.0-3.0 :
· Treatment of Venous thrombosis & Pulmonary embolism
· Prophylaxis of Venous thrombosis (High risk surgery)
· Prevention of systemic embolism in tissue heart valves, AMI, Valvular heart disease &
Atrial fibrillation
· Bileaflet mechanical valve in aortic position
INR 2.5-3.5:
§ Mechanical prosthetic valves
§ Systemic recurrent emboli

Comments
Prothrombin time measures the extrinsic coagulation pathway which consists of activated Factor VII (VIIa),
Tissue factor and Proteins of the common pathway (Factors X, V, II & Fibrinogen). This assay is used to
control long term oral anticoagulant therapy, evaluation of liver function & to evaluate coagulation disorders
specially factors involved in the extrinsic pathway like Factors V, VII, X, Prothrombin & Fibrinogen.

PatientReportSCSuperPanel.SP_GENERAL_TEMPLATE01_SC (Version: 7)

*311032063*
Page 3 of 6
.

S27 - LPL-SRINAGAR
140-A, KAK SARAI, KARAN NAGAR,
SRINAGAR- 190010, J&K
SRINAGAR

Name : Mr. ISHFAQ SHAFIQ Collected : 2/7/2021 10:03:00AM

Received : 2/7/2021 10:15:01AM
Lab No. : 311032063 Age: 29 Years Gender: Male Reported : 3/7/2021 4:28:12PM
A/c Status : P Ref By : Dr. ZEESHAN Report Status : Final

Test Name Results Units Bio. Ref. Interval

ANTI NUCLEAR ANTIBODY / FACTOR (ANA/ANF), 10.05 Units <20.00
SERUM @
(EIA)
Interpretation
---------------------------------------------
| RESULT IN UNITS | REMARKS |
|-------------------|-------------------------|
| <20 | Negative |
|-------------------|-------------------------|
| 20-60 | Moderate positive |
|-------------------|-------------------------|
| >60 | Strong positive |
---------------------------------------------

Comments
Antinuclear antibodies are the most sensitive screening test for autoantibodies in patients suspected of
connective tissue diseases. They are a heterogenous group of autoantibodies directed against ds-DNA,
histones, SSA / Ro, SSB / La, Sm, Sm / RNP, Scl-70, Jo-1 & Centromere. ANA ‘s have also been detected in
patients with Autoimmune Hepatitis (80%),Primary biliary cirrhosis (60%), Alcohol related liver disease (50%),
Viral hepatitis B (40%). Presence of ANA has also been detected in individuals taking certain drugs like
Hydrallazine, Isoniazid, Chlorpromazine; family of SLE patients; healthy and elderly persons

MITOCHONDRIAL ANTIBODY (AMA), IFA @

(IFA)

AMA Negative

Titre 1:40

Note: 1. Autoimmune reactivities are not by themselves diagnostic, but must be correlated with other
laboratory & clinical findings
2. Test conducted on Serum
Comments
The most frequently detected Mitochondrial antibody which is of greatest clinical utility is M 2 antibody.
Mitochondrial M2 antibodies have been detected in patients with Primary Biliary cirrhosis (96%) and
occasionally in other Chronic liver diseases and Systemic sclerosis. These antibodies are also detected in

PatientReportSCSuperPanel.SP_GENERAL_TEMPLATE01_SC (Version: 7)

*311032063*
Page 4 of 6
.

S27 - LPL-SRINAGAR
140-A, KAK SARAI, KARAN NAGAR,
SRINAGAR- 190010, J&K
SRINAGAR

Name : Mr. ISHFAQ SHAFIQ Collected : 2/7/2021 10:03:00AM

Received : 2/7/2021 10:15:01AM
Lab No. : 311032063 Age: 29 Years Gender: Male Reported : 3/7/2021 4:28:12PM
A/c Status : P Ref By : Dr. ZEESHAN Report Status : Final

Test Name Results Units Bio. Ref. Interval

asymptomatic patients who later go on to develop Primary Biliary cirrhosis.
SMOOTH MUSCLE ANTIBODY (ASMA) @
(IFA)

ASMA Negative

Titre 1:40

Note: 1. Autoimmune reactivities are not by themselves diagnostic, but must be correlated with other
laboratory & clinical findings
2. Test conducted on Serum

Comments
Smooth muscle antibodies (ASMA) is a specific marker for Autoimmune hepatitis Type I ( 50-80%) & Primary
Biliary Cirrhosis ( 20%). These antibodies are also associated with Chronic viral hepatitis B & C, Non alcoholic
fatty liver disease, Alcoholic cirrhosis & other Autoimmune inflammatory disorders. They have also been
detected in apparently healthy individuals.

Dr.Shazia Bashir Dr Adil Sidique Dr. Ajay Gupta Dr.Sarita Kumari Lal
MD,Pathology MD, Pathology MD, Pathology MD, Pathology
Chief of Laboratory Chief of Laboratory HOD Hematology & Consultant Pathologist
Dr Lal PathLabs Ltd Dr Lal PathLabs Ltd Immunohematology Dr Lal PathLabs Ltd
NRL - Dr Lal PathLabs Ltd

Dr Sunanda
MD, Pathology
Consultant Pathologist
Dr Lal PathLabs Ltd

-------------------------------End of report --------------------------------

PatientReportSCSuperPanel.SP_GENERAL_TEMPLATE01_SC (Version: 7)

*311032063*
Page 5 of 6
.

S27 - LPL-SRINAGAR
140-A, KAK SARAI, KARAN NAGAR,
SRINAGAR- 190010, J&K
SRINAGAR

Name : Mr. ISHFAQ SHAFIQ Collected : 2/7/2021 10:03:00AM

Received : 2/7/2021 10:15:01AM
Lab No. : 311032063 Age: 29 Years Gender: Male Reported : 3/7/2021 4:28:12PM
A/c Status : P Ref By : Dr. ZEESHAN Report Status : Final

Test Name Results Units Bio. Ref. Interval

IMPORTANT INSTRUCTIONS

*Test results released pertain to the specimen submitted .*All test results are dependent on the quality of the sample received by the Laboratory .
*Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring Physician .*Sample
repeats are accepted on request of Referring Physician within 7 days post reporting.*Report delivery may be delayed due to unforeseen
circumstances. Inconvenience is regretted.*Certain tests may require further testing at additional cost for derivation of exact value. Kindly submit
request within 72 hours post reporting.*Test results may show interlaboratory variations .*The Courts/Forum at Delhi shall have exclusive
jurisdiction in all disputes/claims concerning the test(s) & or results of test(s).*Test results are not valid for medico legal purposes. * Contact
customer care Tel No. +91-11-39885050 for all queries related to test results.
(#) Sample drawn from outside source.

PatientReportSCSuperPanel.SP_GENERAL_TEMPLATE01_SC (Version: 7)

*311032063*
Page 6 of 6